دورية أكاديمية
Hormone therapy and fractures in postmenopausal women.
العنوان: | Hormone therapy and fractures in postmenopausal women. |
---|---|
المؤلفون: | Yin MT; Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY., Hoover DR; Department of Statistics and Institute for Health, Healthcare Policy and Aging Research, Rutgers University, Piscataway, NJ., Shi Q; School of Health Sciences and Practice, New York Medical College, Valhalla, NY., Tien PC; Department of Veterans Affairs Medical Center.; Department of Medicine, University of California San Francisco, San Francisco, CA., Cohen MH; Department of Medicine, Stroger Hospital, Chicago, IL., Kassaye S; Georgetown School of Medicine, Washington DC., Gustafson D; State University of New York Downstate Medical Center, Brooklyn, NY., Adimora A; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill., Weitzmann MN; Department of Medicine, Emory University School of Medicine, Atlanta.; the Atlanta VA Medical Center, Decatur, GA., Bolivar H; Department of Medicine, University of Miami, Miami, FL., Warriner A; Department of Medicine, University of Alabama, Birmingham AL., Bares SH; Department of Medicine, University of Nebraska Medical Center, Omaha, NE., Sharma A; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. |
المصدر: | AIDS (London, England) [AIDS] 2022 Oct 01; Vol. 36 (12), pp. 1683-1688. Date of Electronic Publication: 2022 Jun 22. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 1998- : London, England : Lippincott Williams & Wilkins Original Publication: London : Gower Academic Journals, c1987- |
مواضيع طبية MeSH: | Fractures, Bone*/epidemiology , Fractures, Bone*/prevention & control , HIV Infections*/complications , HIV Infections*/drug therapy, Aged ; Female ; Hormones ; Humans ; Postmenopause ; Prospective Studies ; Risk Factors |
مستخلص: | Background: Fracture rates have been reported to be higher among older women living with HIV (WLWH) than HIV- women. Hormone therapy with estrogen can reduce vasomotor symptoms (VMS) associated with menopause and prevent fractures. As data are limited on the benefits of hormone therapy use in WLWH, we examined associations of hormone therapy, use and fractures. Methods: A prospective study of 1765 (1350 WLWH and 415 HIV-) postmenopausal Women's Interagency HIV Study (WIHS) participants was performed, including self-reported hormone therapy, use and fracture data from 2003 to 2017. Proportional hazard models determined predictors of new fractures at any site or at typical fragility fracture sites (hip, spine, wrist). Results: At the first postmenopausal visit, the median (IQR) age of WLWH was slightly younger than HIV- women [49.8 (46.4-53) vs. 50.7 (47.5-54), P = 0.0002] and a smaller proportion of WLWH reported presence of VMS (17% vs. 26%, P < 0.0001). A greater proportion of WLWH than HIV- women reported hormone therapy use (8% vs. 4%, P = 0.007) at the first postmenopausal visit. In multivariate analyses, white race and smoking were significant predictors of incident fracture at any site but hormone therapy ( P = 0.69) and HIV status ( P = 0.53) were not. Conclusion: Our study did not find evidence of benefit or harm with regards to fracture outcomes in postmenopausal WLWH receiving hormone therapy. Further research is needed to determine whether hormone therapy has benefits beyond treatment of VMS, such as prevention of adverse aging-associated outcomes. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
References: | Prior JC. Perimenopause: the complex endocrinology of the menopausal transition . Endocr Rev 1998; 19:397–428. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition . JAMA Intern Med 2015; 175:531–539. Boonyanurak P, Bunupuradah T, Wilawan K, Lueanyod A, Thongpaeng P, Chatvong D, et al. Age at menopause and menopause-related symptoms in human immunodeficiency virus-infected Thai women . Menopause 2012; 19:820–824. de Pommerol M, Hessamfar M, Lawson-Ayayi S, Neau D, Geffard S, Farbos S, et al. Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort . Int J STD AIDS 2011; 22:67–72. Imai K, Sutton MY, Mdodo R, Del Rio C. HIV and menopause: a systematic review of the effects of HIV infection on age at menopause and the effects of menopause on response to antiretroviral therapy . Obstet Gynecol Int 2013; 2013:340309. Van Ommen CE, King EM, Murray MCM. Age at menopause in women living with HIV: a systematic review . Menopause 2021; 28:1428–1436. Looby SE. Symptoms of menopause or symptoms of HIV? Untangling the knot . Menopause 2018; 25:728–730. Schnall R, Jia H, Olender S, Gradilla M, Reame N. In people living with HIV (PLWH), menopause (natural or surgical) contributes to the greater symptom burden in women: results from an online US survey . Menopause 2018; 25:744–752. Agaba PA, Meloni ST, Sule HM, Ocheke AN, Agaba EI, Idoko JA, et al. Prevalence and predictors of severe menopause symptoms among HIV-positive and -negative Nigerian women . Int J STD AIDS 2017; 28:1325–1334. Looby SE, Psaros C, Raggio G, Rivard C, Smeaton L, Shifren J, et al. Association between HIV status and psychological symptoms in perimenopausal women . Menopause 2018; 25:648–656. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women . J Clin Endocrinol Metab 2008; 93:861–868. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system . J Clin Endocrinol Metab 2008; 93:3499–3504. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans . PloS one 2011; 6:e17217. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006 . Clin Infect Dis 2011; 52:1061–1068. Shiau S, Arpadi SM, Yin MT. Bone update: is it still an issue without tenofovir disoproxil fumarate? . Curr HIV/AIDS Rep 2020; 17:1–5. Baber RJ, Panay N, Fenton A. IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy . Climacteric 2016; 19:109–150. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline . J Clin Endocrinol Metab 2015; 100:3975–4011. The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society . Menopause 2017; 24:728–753. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials . BMC Musculoskelet Disord 2001; 2:7. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials . JAMA 2001; 285:2891–2897. Banks E, Beral V, Reeves G, Balkwill A, Barnes I. Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women . JAMA 2004; 291:2212–2220. Duff PK, Money DM, Ogilvie GS, Ranville F, Kestler M, Braschel MC, et al. SHAWNA Project. Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver . Menopause 2018; 25:531–537. King EM, Prior JC, Pick N, van Schalkwyk J, Kestler M, Tkachuk S, et al. Menopausal hormone therapy for women living with HIV . The lancet HIV 2021; 8:e591–e598. Lobo RA. Hormone-replacement therapy: current thinking . Nat Rev Endocrinol 2017; 13:220–231. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial . JAMA 2002; 288:321–333. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial . Jama 2004; 291:1701–1712. Sharma A, Shi Q, Hoover DR, Anastos K, Tien PC, Young MA, et al. Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study . J Acquir Immune Defic Syndr 2015; 70:54–61. Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, et al. Cohort profile: the Women's Interagency HIV Study (WIHS) . Int J Epidemiol 2018; 47:393–394i. D'Souza G, Bhondoekhan F, Benning L, Margolick JB, Adedimeji AA, Adimora AA, et al. Characteristics of the MACS/WIHS Combined Cohort Study: opportunities for research on aging with HIV in the Longest US Observational Study of HIV . Am J Epidemiol 2021; 190:1457–1475. Sharma A, Shi Q, Hoover DR, Tien PC, Plankey MW, Cohen MH, et al. Frailty predicts fractures among women with and at-risk for HIV . AIDS 2019; 33:455–463. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study . AIDS 2010; 24:2679–2686. Rubin LH, Sundermann EE, Cook JA, Martin EM, Golub ET, Weber KM, et al. Investigation of menopausal stage and symptoms on cognition in human immunodeficiency virus-infected women . Menopause 2014; 21:997–1006. Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative . Curr Opin Lipidol 2013; 24:493–499. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative . Arch Intern Med 2006; 166:357–365. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause . JAMA 2007; 297:1465–1477. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease . J Clin Endocrinol Metab 2007; 92:2506–2512. Womack JA, Chang CC, So-Armah KA, Alcorn C, Baker JV, Brown ST, et al. HIV infection and cardiovascular disease in women . J Am Heart Assoc 2014; 3:e001035. |
معلومات مُعتمدة: | U01 AI031834 United States AI NIAID NIH HHS; U01 HL146245 United States HL NHLBI NIH HHS; K24 AI155230 United States AI NIAID NIH HHS; U01 HL146208 United States HL NHLBI NIH HHS; R01 AI095089 United States AI NIAID NIH HHS; U01 HL146192 United States HL NHLBI NIH HHS; UM1 AI069470 United States AI NIAID NIH HHS; U01 HL146242 United States HL NHLBI NIH HHS; U01 HL146193 United States HL NHLBI NIH HHS; U01 AI103390 United States AI NIAID NIH HHS; U01 HL146194 United States HL NHLBI NIH HHS; U01 HL146241 United States HL NHLBI NIH HHS; P30 AI027767 United States AI NIAID NIH HHS; P30 AI050409 United States AI NIAID NIH HHS; U01 HL146333 United States HL NHLBI NIH HHS; U01 HL146205 United States HL NHLBI NIH HHS; P30 MH116867 United States MH NIMH NIH HHS; U01 AI069470 United States AI NIAID NIH HHS; P30 AI073961 United States AI NIAID NIH HHS; U01 HL146201 United States HL NHLBI NIH HHS; U01 HL146204 United States HL NHLBI NIH HHS; U01 HL146202 United States HL NHLBI NIH HHS; UL1 TR001881 United States TR NCATS NIH HHS; UL1 TR000004 United States TR NCATS NIH HHS; U01 HL146240 United States HL NHLBI NIH HHS; U01 HL146203 United States HL NHLBI NIH HHS; UL1 TR003098 United States TR NCATS NIH HHS; P30 AI050410 United States AI NIAID NIH HHS |
المشرفين على المادة: | 0 (Hormones) |
تواريخ الأحداث: | Date Created: 20220622 Date Completed: 20220908 Latest Revision: 20240201 |
رمز التحديث: | 20240201 |
مُعرف محوري في PubMed: | PMC9444941 |
DOI: | 10.1097/QAD.0000000000003292 |
PMID: | 35730385 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1473-5571 |
---|---|
DOI: | 10.1097/QAD.0000000000003292 |